Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cellebrite DI (CLBT) EBITDA (2020 - 2025)

Cellebrite DI's EBITDA history spans 6 years, with the latest figure at $38331.0 for Q4 2025.

  • Quarterly EBITDA rose 33.13% to $38331.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.7 million through Dec 2025, down 80.1% year-over-year, with the annual reading at $127631.0 for FY2025, 28.43% up from the prior year.
  • EBITDA came in at $38331.0 for Q4 2025, down from $19.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $207.9 million in Q3 2024 to a low of -$41.1 million in Q1 2023.
  • The 5-year median for EBITDA is $8.7 million (2021), against an average of $20.4 million.
  • Year-over-year, EBITDA tumbled 175.16% in 2023 and then soared 2719.35% in 2024.
  • Cellebrite DI's EBITDA stood at $4.3 million in 2021, then soared by 90.04% to $8.2 million in 2022, then skyrocketed by 70.95% to $14.0 million in 2023, then crashed by 99.79% to $28793.0 in 2024, then skyrocketed by 33.13% to $38331.0 in 2025.
  • Per Business Quant, the three most recent readings for CLBT's EBITDA are $38331.0 (Q4 2025), $19.0 million (Q3 2025), and $14.4 million (Q2 2025).